Physician profile
Stanley Ng
NPI 1760671317
$23,425.51
in general payments reported to CMS, 2019-2025
22 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,585 · 2021: $721 · 2022: $1,007 · 2023: $1,559 · 2024: $1,460 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18,348.46 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $908.10 | 2019-2022 | |
| Gilead Sciences, INC. | $780.61 | 2023-2025 | Vemlidy, Epclusa |
| Astrazeneca Pharmaceuticals Lp | $712.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $380.82 | 2021-2024 | Nexletol |
| Medtronic, INC. | $378.59 | 2022-2025 | Symplicity G3 |
| Lilly USA, LLC | $291.39 | 2019-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $263.22 | 2022-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $184.21 | 2019 | |
| Glaxosmithkline, LLC. | $165.44 | 2023-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.32 | 2019-2024 | Jardiance |
| Axsome Therapeutics, INC. | $142.02 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $132.50 | 2023 | Quviviq |
| Pfizer INC. | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124.04 | 2020 | |
| Optinose US, INC. | $104.91 | 2021 | |
| Merck Sharp & Dohme LLC | $21.92 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $21.77 | 2024 | |
| Abbvie INC. | $18.94 | 2024 | |
| Baxter Healthcare | $17.24 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.